Gillian C. Bell

1.4k total citations · 1 hit paper
23 papers, 735 citations indexed

About

Gillian C. Bell is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Genetics. According to data from OpenAlex, Gillian C. Bell has authored 23 papers receiving a total of 735 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 8 papers in Pediatrics, Perinatology and Child Health and 5 papers in Genetics. Recurrent topics in Gillian C. Bell's work include Pharmacogenetics and Drug Metabolism (10 papers), Pharmaceutical studies and practices (7 papers) and BRCA gene mutations in cancer (4 papers). Gillian C. Bell is often cited by papers focused on Pharmacogenetics and Drug Metabolism (10 papers), Pharmaceutical studies and practices (7 papers) and BRCA gene mutations in cancer (4 papers). Gillian C. Bell collaborates with scholars based in United States, Australia and Canada. Gillian C. Bell's co-authors include J. Kevin Hicks, Henry M. Dunnenberger, Howard L. McLeod, Peter J. Hulick, Janardan D. Khandekar, Samuel G. Johnson, Donald K. Baker, Robert R. Freimuth, James M. Hoffman and Mary V. Relling and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Investigative Dermatology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Gillian C. Bell

22 papers receiving 711 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants

2023 181 citations Chad Bousman, James M. Stevenson et al. Clinical Pharmacology & Therapeutics profile →

Peers

Countries citing papers authored by Gillian C. Bell

Since Specialization

Citations

This map shows the geographic impact of Gillian C. Bell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gillian C. Bell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gillian C. Bell more than expected).

Fields of papers citing papers by Gillian C. Bell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gillian C. Bell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gillian C. Bell. The network helps show where Gillian C. Bell may publish in the future.

Co-authorship network of co-authors of Gillian C. Bell

This figure shows the co-authorship network connecting the top 25 collaborators of Gillian C. Bell. A scholar is included among the top collaborators of Gillian C. Bell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gillian C. Bell. Gillian C. Bell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants breakdown → 2023 ·Clinical Pharmacology & Therapeutics ·Chad Bousman, James M. Stevenson, Laura B. Ramsey, Katrin Sangkuhl, J. Kevin Hicks, Jeffrey R. Strawn, Ajeet Singh, Gualberto Ruaño, Daniel Mueller, Evangelia Eirini Tsermpini, Jacob T. Brown, Gillian C. Bell, J. Steven Leeder, Andrea Gaedigk, Stuart A. Scott, Teri E. Klein, Kelly E. Caudle, Jeffrey R. Bishop	181
2	A clinician’s guide for counseling patients on results of a multigene pharmacogenomic panel 2022 ·American Journal of Health-System Pharmacy ·(unknown), Gillian C. Bell, Roseann S. Gammal, (unknown), Dyson T. Wake, Henry M. Dunnenberger	6
3	Synthesis of Major Pharmacogenomics Pretest Counseling Themes: A Multisite Comparison 2021 ·Pharmacogenomics ·Dyson T. Wake, Gillian C. Bell, (unknown), (unknown), Henry M. Dunnenberger	10
4	A One Health investigation of Salmonella enterica serovar Wangata in north-eastern New South Wales, Australia, 2016–2017 2019 ·Epidemiology and Infection ·Julie Collins, K. M. Simpson, Gillian C. Bell, David N Dürrheim, Grant Hill-Cawthorne, Kirsty Hope, Peter Howard, (unknown), KE Lawrence, (unknown), (unknown), Vitali Sintchenko, (unknown), Michael P. Ward, Anke Wiethoelter, Siobhan M. Mor, James Flint	11
5	Implementing a Personalized Medicine Cancer Program in a Community Cancer System 2019 ·Personalized Medicine ·Lynn G. Dressler, Gillian C. Bell, (unknown), Mark Steciuk, Oliver A.R. Binns, Rachel Raab, (unknown), Carolyn M. Wilson, (unknown), (unknown), (unknown), Michael J. Messino	6
6	Implementing Pharmacogenetic Testing in Rural Primary Care Practices: A Pilot Feasibility Study 2019 ·Pharmacogenomics ·Lynn G. Dressler, Gillian C. Bell, (unknown), (unknown), Sheri Denslow	19
7	Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors 2018 ·Supportive Care in Cancer ·Sonam Puri, Kelly A. Hyland, (unknown), Gillian C. Bell, Jhanelle E. Gray, Richard D. Kim, Hui‐Yi Lin, Aasha I. Hoogland, Brian D. Gonzalez, Ashley M. Nelson, Anita Y. Kinney, Stacy M. Fischer, Daneng Li, Paul B. Jacobsen, Howard L. McLeod, Heather Jim	19
8	Implementing a Personalized Medicine Program in a Community Health System 2018 ·Pharmacogenomics ·Lynn G. Dressler, Gillian C. Bell, (unknown), (unknown), (unknown), Ronald A. Paulus	15
9	Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort 2017 ·Journal of Investigative Dermatology ·Nancy Gillis, (unknown), Gillian C. Bell, (unknown), Peter A. Kanetsky, Howard L. McLeod	22
10	Pharmacogenomics Implementation: Considerations for Selecting a Reference Laboratory 2017 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), Gillian C. Bell, Aniwaa Owusu Obeng, J. Kevin Hicks, Henry M. Dunnenberger	37
11	Key Lessons Learned from Moffitt’s Molecular Tumor Board: The Clinical Genomics Action Committee Experience 2017 ·The Oncologist ·Todd C. Knepper, Gillian C. Bell, J. Kevin Hicks, Eric Padron, Jamie K. Teer, (unknown), Nancy Gillis, Neil Mason, (unknown), Christine M. Walko	49
12	Implementation of a multidisciplinary pharmacogenomics clinic in a community health system 2016 ·American Journal of Health-System Pharmacy ·Henry M. Dunnenberger, (unknown), Gillian C. Bell, (unknown), (unknown), Samuel G. Johnson, Peter J. Hulick, Janardan D. Khandekar	95
13	Detection of a PDGFRB fusion in refractory CMML without eosinophilia: A case for broad spectrum tumor profiling 2015 ·Leukemia Research Reports ·Gillian C. Bell, Eric Padron	7
14	Budget impact analysis ofCYP2C19-guided voriconazole prophylaxis in AML 2015 ·Journal of Antimicrobial Chemotherapy ·Neil Mason, Gillian C. Bell, (unknown), John N. Greene, Howard L. McLeod	14
15	Clinical Implications of Opioid Pharmacogenomics in Patients with Cancer 2015 ·Cancer Control ·Gillian C. Bell, Kristine A. Donovan, Howard L. McLeod	19
16	Budget Impact Analysis of CYP2C19 Genotyping to Target Voriconazole Prophylaxis During Induction-Consolidation Therapy in Acute Myeloid Leukemia (AML) in The United States 2014 ·Value in Health ·Neil Mason, Gillian C. Bell, Howard L. McLeod	0
17	Development and use of active clinical decision support for preemptive pharmacogenomics 2013 ·Journal of the American Medical Informatics Association ·Gillian C. Bell, Kristine R. Crews, Mark R. Wilkinson, Cyrine E. Haidar, J. Kevin Hicks, Donald K. Baker, Nancy M. Kornegay, Wenjian Yang, Shane J. Cross, Scott C. Howard, Robert R. Freimuth, William E. Evans, Ulrich Broeckel, Mary V. Relling, James M. Hoffman	159
18	Evaluation of regional limb perfusion with amikacin using the saphenous, cephalic, and palmar digital veins in standing horses 2012 ·Journal of Veterinary Pharmacology and Therapeutics ·Gal Kelmer, Gillian C. Bell, Tomás Martín‐Jiménez, Arnold M. Saxton, (unknown), (unknown), Bernd Meibohm	34
19	2010 pertussis outbreak and updated Tdap recommendations 2011 ·Journal of the American Pharmacists Association ·Gillian C. Bell, Stephan L. Foster	3
20	Faculty and Student Perceptions of Effective Study Strategies and Materials 2011 ·American Journal of Pharmaceutical Education ·Katie J. Suda, Gillian C. Bell, Andrea S. Franks	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact